

Press Release

November 28th, 2000

CellaVision signs Letter of Intent with Sysmex

CellaVision AB (situated in Sweden) and Sysmex Europe GmbH (situated in Germany) have signed a Letter of Intent regarding distribution of CellaVision's products in selected countries, including Germany as an initial target.

Discussions regarding this and potential development collaboration within digital imaging and analysis in hematology will be conducted and concluded during the next couple of months. "We are now about to enter the commercial phase of our unique technology developments", says Yvonne Mårtensson, CEO CellaVision AB. "Our first product, DiffMaster™, has passed the clinical test phase and is now ready for launch. Sysmex may turn out to be a perfect partner for us in our attempts to penetrate the market with the highest possible speed".

For further information please contact:

Yvonne Mårtensson, CEO CellaVision AB

Tel +46 (0)46-286 5820, Mobile +46 (0)708-33 77 82, yvonne.martensson@cellavision.se

CellaVision AB is a Swedish high technology company whose core competence is development of software for automatic image analysis of cells and cell changes with applications within healthcare. The company represents unique competence within the field of advanced image processing, image analysis and automated microscopy. Today CellaVision offers two products: DiffMaster[®] and CellAtlas[®], both of which are built on CellaVision's cell image database and are tools for facilitating cell analysis and diagnosis. Most of the 40 employees are dedicated to software development. For further information, please visit www.cellavision.com.

Sysmex Europe, Subsidiary of Sysmex Japan, a world leading company in instrumentation and software for Haematology Laboratories with worldwide market coverage through own subsidiaries and distributors.